CeriBell (CBLL) has just posted Q1 2026 results, reporting total revenue of US$26.5 million and a basic EPS loss of US$0.52. The company also reported trailing twelve month revenue of US$95.1 million and a TTM basic EPS loss of US$1.63 at a share price of US$16.75. Over recent quarters the company has seen quarterly revenue move from US$18.5 million in Q4 2024 to US$26.5 million in Q1 2026, while quarterly basic EPS losses shifted from US$0.40 to US$0.52. This keeps the focus firmly on how quickly margins can narrow from here.

See our full analysis for CeriBell.

With the latest numbers on the table, the next step is to see how this mix of revenue growth and ongoing losses lines up with the key narratives investors have been following around CeriBell.

Wider Q1 loss despite higher TTM revenue

• On a trailing twelve month basis, revenue sits at US$95.1 million while TTM net loss is US$60.4 million, with Q1 2026 net loss at US$19.7 million compared with US$13.5 million in Q4 2025.
• Consensus narrative highlights strong revenue momentum around a forecast 20.5% annual growth rate. However, the multi year pattern of widening losses of about 21.2% a year and expectations that the company stays unprofitable for at least three more years keep profitability firmly in focus for both optimistic and cautious investors.
  • Supporters of the growth story can point to the move in quarterly revenue from US$18.5 million in Q4 2024 to US$26.5 million in Q1 2026 and TTM revenue rising from US$65.4 million in Q4 2024 to US$95.1 million in Q1 2026.
  • On the other side, critics underline that quarterly net loss widened from US$12.6 million in Q4 2024 to US$19.7 million in Q1 2026 while TTM loss increased from US$40.5 million to US$60.4 million over the same span, which lines up with the data showing losses growing faster than revenue.

To see how these trends fit into the wider story that other investors are debating, it is worth checking the full community view on CeriBell, including how people are weighing growth against losses and valuation signals, via the See what the community is saying about CeriBell.

Premium P/S multiple at 6.7x

• The stock trades on a P/S of 6.7x, compared with 2.7x for the broader US Medical Equipment industry and 3.7x for a defined peer set. This means investors are currently paying a higher sales multiple for CeriBell than for many sector peers.
• Consensus narrative flags this higher multiple as a key tension point because strong forecast revenue growth near 20.5% a year is being weighed against a rich sales multiple and ongoing losses, so investors are effectively paying up for growth while the company is still loss making.
  • Supporters argue that the premium can be explained by above market revenue growth and by analyst expectations that the share price could move toward an average target of US$26.86, which is above the current US$16.75 price.
  • Skeptics focus on the combination of a 6.7x P/S ratio and a TTM net loss of US$60.4 million, pointing out that the company is priced higher than many peers on sales while still reporting significant losses that analysts do not expect to reverse into profits in the next three years.

Analysts see upside despite insider selling

• Analysts as a group indicate potential upside of about 60.3% from the current US$16.75 share price to an average target of roughly US$26.86, even as recent data records material insider selling over the past three months.
• What stands out in the consensus narrative is the contrast between that implied upside and the risk signals, as the same dataset points to persistent losses, a 6.7x P/S multiple and meaningful insider sales, which gives investors a mix of supportive and cautionary markers to weigh.
  • On the supportive side, the combination of forecast revenue growth around 20.5% a year and an analyst average target above the current share price is the core of the reward case set out in the summary.
  • On the cautionary side, the record of insider selling alongside expectations that the company remains unprofitable for at least three years highlights why some investors focus more on risk metrics and capital needs than on price targets alone.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for CeriBell on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Given the mix of optimism and caution throughout this update, it makes sense to review the numbers, sentiment and key signals for yourself before reacting. To help frame that view, take a close look at the 2 key rewards and 2 important warning signs.

Explore Alternatives

CeriBell combines a premium 6.7x P/S ratio with ongoing losses of US$60.4 million TTM and expectations for at least three more years without profitability.

If you are uneasy about paying up for a loss making stock at a rich sales multiple, it is worth comparing it with 45 high quality undervalued stocks today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.